P-066

Pregabalin -Lösung

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• Empirische Formel (Hill-System): C₈H₁₇NO₂
• CAS-Nummer: 148553-50-8
• Molekulargewicht: 159.23
• EG-Nummer: 200-659-6
• MDL-Nummer: MFCD00906155
• UNSPSC-Code: 41116107
• PubChem Substanz-ID: 329820047
• NACRES: NA.24

Eigenschaften

• Qualität: certified reference material
• Form: liquid
• Leistungsmerkmale: Snap-N-Spike^®/Snap-N-Shoot^®
• Verpackung: ampule of 1 mL
• Hersteller/Markenname: Cerilliant^®
• Konzentration: 1.0 mg/mL in methanol
• Methode(n): gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• Anwendung(en): clinical testing
• Format: single component solution
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• SMILES String: CC(CC([H])(CN)CC(O)=O)C
• InChI: 1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)
• InChIKey: AYXYPKUFHZROOJ-UHFFFAOYSA-N

Beschreibung

Allgemeine Beschreibung

Pregabalin, das unter den Handelsnamen Lyrica^® verkauft wird, ist ein Antiepileptikum, das vorwiegend zur Behandlung von Krampfanfällen, Fibromyalgie, diabetischer peripherer Neuropathie, generalisierter Angststörung und chronischen neuropathischen Schmerzen eingesetzt wird. Dieser zertifizierte Referenzstandard eignet sich für Pregabalin-GC/MS- bzw. LC/MS-Untersuchungen in der forensischen Analytik, klinischen Toxikologie, Schmerzmittelüberwachung oder Urin-Drogenkontrolle.

Anwendung

• Evaluation of Pregabalin and Dexamethasone Coadministration: This study assesses the effects of Pregabalin combined with dexamethasone on preemptive multimodal analgesia and anxiety management during third molar surgeries. The trial highlighted its potential to significantly improve patient outcomes in dental procedures (Diniz et al., 2024).


• Interactions with Antiepileptic Drugs: This article explores how Pregabalin interacts with other antiepileptic drugs when used for primary and secondary stroke prevention, particularly focusing on its compatibility and potential interactions in clinical settings (Stöllberger & Finsterer, 2024).


• Molecular Docking Analysis: This research utilizes molecular docking techniques to analyze Pregabalin and other marine compounds targeting voltage-gated calcium channels, aiming to identify potential anti-epileptic molecules (Sheokand et al., 2024).


• Management of Neuropathic Pain in Cats: Focused on veterinary medicine, this review discusses the mechanisms of neuropathic pain in cats and how Pregabalin, among other treatments, can be used for multimodal pain management (Rusbridge, 2024).


• Pharmacotherapy and Noninvasive Neurostimulation: This article reviews current pharmacotherapies including Pregabalin and noninvasive neurostimulation techniques for treating neuropathic pain, providing an overview of effective pain management strategies (Spagna & Attal, 2024).

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Lyrica is a registered trademark of C.P. Pharmaceuticals International C.V.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Sicherheitshinweise

• Piktogramme: GHS02,GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H225,H301 + H311 + H331,H370
• P-Sätze: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• Gefahreneinstufungen: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Zielorgane: Eyes,Central nervous system
• Lagerklassenschlüssel: 3 - Flammable liquids
• WGK: WGK 2
• Flammpunkt (°F): 49.5 °F - closed cup
• Flammpunkt (°C): 9.7 °C - closed cup